Evidence map›Paper›PMID 38850022›Full record

SynthesisHGG advances2024

Identification of novel driver risk genes in CNV loci associated with neurodevelopmental disorders.

Sara Azidane, Xavier Gallego, Lynn Durham, Mario Cáceres, Emre Guney, Laura Pérez-Cano

Abstract readMeta-Analysis
In one paragraph

Synthesis in HGG advances, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Review
  2. Clinical,medRxiv : the preprint server for health sciences · 2026
    Article
  3. Article
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Sara AzidaneSTALICLA Discovery and Data Science Unit, World Trade Center, Moll de Barcelona, Edif Este, 08039 Barcelona, Spain; Institut de Biotecnologia i de Biomedicina, Universitat Autònoma de Barcelona, Bellaterra, 08193 Barcelona, Spain.
Xavier GallegoSTALICLA Discovery and Data Science Unit, World Trade Center, Moll de Barcelona, Edif Este, 08039 Barcelona, Spain.
Lynn DurhamSTALICLA Discovery and Data Science Unit, World Trade Center, Moll de Barcelona, Edif Este, 08039 Barcelona, Spain.
Mario CáceresInstitut de Biotecnologia i de Biomedicina, Universitat Autònoma de Barcelona, Bellaterra, 08193 Barcelona, Spain; ICREA, 08010 Barcelona, Spain; Research Programme on Biomedical Informatics (GRIB), Hospital del Mar Research Institute, Barcelona, Spain.
Emre GuneySTALICLA Discovery and Data Science Unit, World Trade Center, Moll de Barcelona, Edif Este, 08039 Barcelona, Spain.
Laura Pérez-CanoSTALICLA Discovery and Data Science Unit, World Trade Center, Moll de Barcelona, Edif Este, 08039 Barcelona, Spain. Electronic address: laura.perez-cano@stalicla.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Copy-number variants (CNVs) are genome-wide structural variations involving the duplication or deletion of large nucleotide sequences. While these types of variations can be commonly found in humans, large and rare CNVs are known to contribute to the development of various neurodevelopmental disorders (NDDs), including autism spectrum disorder (ASD). Nevertheless, given that these NDD-risk CNVs cover broad regions of the genome, it is particularly challenging to pinpoint the critical gene(s) responsible for the manifestation of the phenotype. In this study, we performed a meta-analysis of CNV data from 11,614 affected individuals with NDDs and 4,031 control individuals from SFARI database to identify 41 NDD-risk CNV loci, including 24 novel regions. We also found evidence for dosage-sensitive genes within these regions being significantly enriched for known NDD-risk genes and pathways. In addition, a significant proportion of these genes was found to (1) converge in protein-protein interaction networks, (2) be among most expressed genes in the brain across all developmental stages, and (3) be hit by deletions that are significantly over-transmitted to individuals with ASD within multiplex ASD families from the iHART cohort. Finally, we conducted a burden analysis using 4,281 NDD cases from Decipher and iHART cohorts, and 2,504 neurotypical control individuals from 1000 Genomes and iHART, which resulted in the validation of the association of 162 dosage-sensitive genes driving risk for NDDs, including 22 novel NDD-risk genes. Importantly, most NDD-risk CNV loci entail multiple NDD-risk genes in agreement with a polygenic model associated with the majority of NDD cases.

Indexed as

Autism Spectrum DisorderDNA Copy Number VariationsGenetic Predisposition to DiseaseNeurodevelopmental DisordersGenome-Wide Association StudyHumansProtein Interaction Mapsautism spectrum disorderburden testingCopy number variantsDecipher databasedosage-sensitive genesiHART cohortneurodevelopmental disordersrisk genes and pathwaysSFARI databasestructural variants

Identifiers

PMID38850022
PMCPMC11264174

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.